Description
Stevanato Group S.p.A.: Expansion & Efficiency In Product Lines
Stevanato Group has presented a mixed performance in the second quarter of 2024, which led to revised expectations for its annual outlook. On the positive side, the company reported a 2% increase in revenue to EUR 260 million, driven by a strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment, which saw a 9% growth. This growth was largely fueled by high-performance syringes, contributing significantly to the product diversity and revenue from high-value solutions, which increased by 23%.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
